Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Hepatitis

Free Subscription Articles published in Gastroenterol Hepatol Retrieve available abstracts of 35 articles: HTML format

Single Articles

December 2023
1. CONTHE A, Ahumada A, Gallego Duran R, Marti-Aguado D, et al
   Current dilemmas in hepatitis virus C management. What should we do after achieving sustained virologic response?
   Gastroenterol Hepatol. 2023;46:826-829.
   PubMed    
   
   
   
2. RIVEIRO-BARCIELA M, Roade L, Martinez-Camprecios J, Vidal-Gonzalez J, et al
   mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels).
   Gastroenterol Hepatol. 2023;46:764-773.
   PubMed     Abstract available
   
   
   
3. ARZALLUS T, Izagirre A, Castiella A, Torrente S, et al
   Drug induced autoimmune hepatitis after turmeric intake.
   Gastroenterol Hepatol. 2023;46:805-806.
   PubMed    
   
   
   August 2023
4. CALLEJA PANERO JL, de la Poza G, Hidalgo L, Aguilera Sancho-Tello MV, et al
   Patient journey of individuals tested for HCV in Spain: LiverTAI, a retrospective analysis of EHRs through natural language processing.
   Gastroenterol Hepatol. 2023;46:491-503.
   PubMed     Abstract available
   
   
   April 2023
5. PEREZ-HERNANDEZ FJ, Morales-Arraez DE, Amaral-Gonzalez C, Gonzalez-Mendez Y, et al
   Asynchronous electronic consultation between primary care and specialized care proved effective for continuum of care for viraemic hepatitis C patients.
   Gastroenterol Hepatol. 2023;46:266-273.
   PubMed     Abstract available
   
   
   
6. HUANG J, Liu Y, Liu Y
   Antiviral therapy in hepatitis B virus-infected with immune-tolerant: A meta-analysis.
   Gastroenterol Hepatol. 2023;46:309-318.
   PubMed     Abstract available
   
   
   February 2023
7. MARTINEZ RAMIREZ NM, Gonzalez Praetorius A, Martinez Benito Y, Garcia Rivera MV, et al
   Changes in the epidemiology of hepatitis A: Clinical and preventive implications.
   Gastroenterol Hepatol. 2023;46:116-123.
   PubMed     Abstract available
   
   
   January 2023
8. FRAILE-LOPEZ M, Alvarez-Navascues C, Gonzalez-Dieguez ML, Cadahia V, et al
   Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C.
   Gastroenterol Hepatol. 2023 Jan 27:S0210-5705(23)00013.
   PubMed     Abstract available
   
   
   
9. NEOKOSMIDIS G, Protopapas AA, Stogiannou D, Filippidis A, et al
   Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C.
   Gastroenterol Hepatol. 2023;46:58-66.
   PubMed     Abstract available
   
   
   
10. SHARKAWI FZE, El-Sherbiny M, Ali SAM, Nassif WMH, et al
    The potential value of plasma Circ-ITCH in hepatocellular carcinoma patients with current hepatitis C virus infection.
    Gastroenterol Hepatol. 2023;46:17-27.
    PubMed     Abstract available
    
    
    December 2022
11. MARTINEZ-CAMPRECIOS J, Riveiro-Barciela M, Munoz-Gomez R, Londono MC, et al
    [Not Available].
    Gastroenterol Hepatol. 2022 Dec 27:S0210-5705(22)00313.
    PubMed    
    
    
    November 2022
12. GARRIDO-ESTEPA M, Herruzo R, Flores-Herrera J
    Co-infections, comorbidities, and alcohol or other substances abuses in chronic hepatitis C-related hospitalisations in Spain.
    Gastroenterol Hepatol. 2022;45:677-689.
    PubMed     Abstract available
    
    
    October 2022
13. CRESPO J, Cabezas J, Aguilera A, Berenguer M, et al
    Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction.
    Gastroenterol Hepatol. 2022 Oct 15. pii: S0210-5705(22)00235.
    PubMed    
    
    
    
14. CUNHA-SILVA M, Torres LD, Fernandes MF, Secundo TML, et al
    Changes in indications for outpatient percutaneous liver biopsy over 5 years: from hepatitis C to fatty liver disease.
    Gastroenterol Hepatol. 2022;45:579-584.
    PubMed     Abstract available
    
    
    August 2022
15. LAVIN AC, Cabezas J, Crespo J
    Letter to the editor in response to the recently published article "Roncero C, Buch B, Martin-Sanchez AM, et al. Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis. Gastroenterol Hepato
    Gastroenterol Hepatol. 2022 Aug 11. pii: S0210-5705(22)00183.
    PubMed    
    
    
    June 2022
16. RONCERO C, Buch B, Martin-Sanchez AM, Alvarez-Navares AI, et al
    Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis.
    Gastroenterol Hepatol. 2022 Jun 30. pii: S0210-5705(22)00172.
    PubMed     Abstract available
    
    
    
17. GUTIERREZ-ROJAS L, de la Gandara Martin JJ, Garcia Buey L, Uriz Otano JI, et al
    Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: results of a literature review.
    Gastroenterol Hepatol. 2022 Jun 16. pii: S0210-5705(22)00164.
    PubMed     Abstract available
    
    
    May 2022
18. ANDRES L, Badia E, Fernandez C, Puebla A, et al
    AUTOIMMUNE HEPATITIS. ANOTHER CONSEQUENCE OF COVID-19?
    Gastroenterol Hepatol. 2022 May 13. pii: S0210-5705(22)00150.
    PubMed    
    
    
    
19. CHEN M, Wu Z, Du Z, Sun S, et al
    Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting liver fibrosis in patients with chronic hepatitis B: A meta-analysis.
    Gastroenterol Hepatol. 2022;45:361-372.
    PubMed     Abstract available
    
    
    April 2022
20. TORRENTE S, Castiella A, Garmendia M, Zapata E, et al
    Probable autoimmune hepatitis reactivated after COVID-19 vaccination.
    Gastroenterol Hepatol. 2022;45 Suppl 1:115-116.
    PubMed    
    
    
    
21. MACIA-RODRIGUEZ C, Santome Couto L, Fernandez Villaverde A, Romero Reinoso C, et al
    Mycophenolate mofetil as a treatment of severe steroid-resistant immune-related hepatitis.
    Gastroenterol Hepatol. 2022;45 Suppl 1:32-36.
    PubMed    
    
    
    March 2022
22. NUNEZ F P, Quera R, Bay C, Thomson P, et al
    Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases.
    Gastroenterol Hepatol. 2022;45:223-230.
    PubMed     Abstract available
    
    
    
23. PEREZ JIMENEZ RD, Granados Monzon R, Hernandez Febles M, Pena Lopez MJ, et al
    Acute hepatitis due to the hepatitisC virus: Where are the transmission occurring?
    Gastroenterol Hepatol. 2022;45:192-197.
    PubMed     Abstract available
    
    
    February 2022
24. ARANDA EB, Marcos CF, Maestu AP, Marin VG, et al
    EVOLUTION OF HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS CURED WITH DIRECT-ACTING ANTIVIRALS. LONG-TERM FOLLOW-UP.
    Gastroenterol Hepatol. 2022 Feb 18. pii: S0210-5705(22)00064.
    PubMed     Abstract available
    
    
    
25. RASHIDI A, Sedaghat F, Nejat A, Azarpira N, et al
    Immunity to hepatitis A virus in liver transplant recipients: A population-based study in Iran.
    Gastroenterol Hepatol. 2022;45:99-105.
    PubMed     Abstract available
    
    
    
26. ROCHA HC, Vilela EG
    Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
    Gastroenterol Hepatol. 2022;45:83-90.
    PubMed     Abstract available
    
    
    December 2021
27. OLIVAS I, Cobreros M, Londono MC, Diaz-Gonzalez A, et al
    Budesonide in the first line treatment of patients with autoimmune hepatitis.
    Gastroenterol Hepatol. 2021 Dec 16. pii: S0210-5705(21)00319.
    PubMed     Abstract available
    
    
    October 2021
28. CALVET X, Carpio D, Rodriguez-Lago I, Garcia-Vicuna R, et al
    Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
    Gastroenterol Hepatol. 2021;44:587-598.
    PubMed     Abstract available
    
    
    September 2021
29. GARCIA-FRAILE LJ, Garcia-Buey L, Cerezo CA, Sanz JS, et al
    ENGLISH: Evolution of HCV associated Porphyria Cutanea Tarda after HCV Sustained Virologic Response by Direct Acting Antivirals.
    Gastroenterol Hepatol. 2021 Sep 22. pii: S0210-5705(21)00248.
    PubMed     Abstract available
    
    
    
30. DE CANETE CAMACHO JCF, Martinez AM, Mena MAG, Maria Moreno Planas J, et al
    Influence of psychiatric disorders and opioid substitution therapy on hepatitis c treatment with direct-acting antivirals in people who inject drugs.
    Gastroenterol Hepatol. 2021 Sep 17. pii: S0210-5705(21)00251.
    PubMed     Abstract available
    
    
    
31. CAMARERO JG, Aranda EB, Castro RQ, Chumillas RMS, et al
    Hepatitis B And C Screening In Hospitalized Patients With Sars-Cov-2 Infection.
    Gastroenterol Hepatol. 2021 Sep 8. pii: S0210-5705(21)00250.
    PubMed     Abstract available
    
    
    June 2021
32. TURNES J, Rincon D, Calleja JL, Delgado MB, et al
    Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naive non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
    Gastroenterol Hepatol. 2021 Jun 12. pii: S0210-5705(21)00198.
    PubMed     Abstract available
    
    
    May 2021
33. REYGOSA C, Arraez DM, Hernandez-Bustabad A, Baute LM, et al
    Hepatitis C-Treated Patients As A Potential Source For Referral Of New Cases.
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00148.
    PubMed     Abstract available
    
    
    April 2021
34. BUSTA NISTAL MR, Garcia Sanchez MC, Mora Cuadrado N, Dura Gil M, et al
    Cholestatic hepatitis as a presentation of secondary syphilis.
    Gastroenterol Hepatol. 2021 Apr 16. pii: S0210-5705(21)00117.
    PubMed    
    
    
    
35. COSTA CA, Garcia JLR, Gandia MAR, Martos RF, et al
    FULMINANT LIVER FAILURE DUE TO HEPATITIS B REACTIVATION DURING THE COVID-19 PANDEMIC.
    Gastroenterol Hepatol. 2021 Apr 13. pii: S0210-5705(21)00118.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.